Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2014

Collaboration Agreement [Abstract]

Collaboration revenue with related party

Sanofi collaboration revenue, as detailed below, consisted primarily of reimbursement for research and development expenses that the Company incurred, partly offset by sharing of pre-launch commercialization expenses in connection with the companies' antibody collaboration. In addition, Sanofi collaboration revenue for the nine months ended September 30, 2013 was reduced by two$10.0 million up-front payments to Sanofi in connection with the Company's acquisition from Sanofi of full exclusive rights to two families of novel antibodies, as described below.

	Three months ended September 30,
Sanofi Collaboration Revenue	2014			2013
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(1,008	)	$	(6,575	)
Reimbursement of Regeneron research and development expenses	1,261			1,316
Other	756			2,625
Total ZALTRAP	1,009			(2,634		)
Antibody:
Reimbursement of Regeneron research and development expenses	140,497			133,128
Regeneron's share of commercialization expenses	(12,830		)	—
Other	4,249			3,865
Total Antibody	131,916			136,993
Total Sanofi collaboration revenue	$	132,925		$	134,359

	Nine months ended September 30,
Sanofi Collaboration Revenue	2014			2013
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(4,912	)	$	(22,581	)
Reimbursement of Regeneron research and development expenses	3,691			5,497
Other	4,417			6,610
Total ZALTRAP	3,196			(10,474		)
Antibody:
Reimbursement of Regeneron research and development expenses	405,212			338,027
Regeneron's share of commercialization expenses	(17,125		)	—
Up-front payments to Sanofi for acquisition of rights related to two antibodies	—			(20,000		)
Other	14,745			11,608
Total Antibody	402,832			329,635
Total Sanofi collaboration revenue	$	406,028		$	319,161

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Three months ended September 30,
Bayer HealthCare Collaboration Revenue	2014		2013
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	85,351	$	31,769
Sales and substantive development milestones	30,000		45,000
Cost-sharing of Regeneron EYLEA development expenses	4,394		3,739
Other	12,745		8,075
Total EYLEA	132,490		88,583
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	518		—
Other	2,845		—
Total PDGFR-beta	3,363		—
Total Bayer HealthCare collaboration revenue	$	135,853	$	88,583

	Nine months ended September 30,
Bayer HealthCare Collaboration Revenue	2014		2013
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	213,291	$	57,186
Sales and substantive development milestones	75,000		45,000
Cost-sharing of Regeneron EYLEA development expenses	26,235		13,207
Other	34,490		19,201
Total EYLEA	349,016		134,594
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	1,657		—
Other	7,787		—
Total PDGFR-beta	9,444		—
Total Bayer HealthCare collaboration revenue	$	358,460	$	134,594